CellFE Launches First-in-Class T-REST™ Kit to Advance CAR-T Therapy Manufacturing

Portfolio company CellFE has unveiled the T-REST™ Kit, a groundbreaking solution designed to enhance CAR-T therapy manufacturing by improving T-cell fitness and function during cell engineering. This first-in-class kit integrates seamlessly into existing workflows, preserving cell viability and accelerating the development of life-saving immunotherapies. By reducing cellular stress and maintaining potency, T-REST™ represents a major step forward in optimizing CAR-T cell therapies for better patient outcomes.